Rohto Pharmaceutical Co.,Ltd.
TSE:4527.T
3383 (JPY) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 270,840 | 238,664 | 199,646 | 181,053 | 188,375 | 183,672 | 171,795 | 154,599 | 166,477 | 151,994 | 144,082 | 128,666 | 120,423 | 115,262 | 113,430 | 110,601 | 108,206 |
Cost of Revenue
| 115,906 | 101,243 | 83,157 | 74,326 | 74,135 | 74,048 | 70,746 | 63,254 | 67,250 | 61,395 | 57,924 | 52,792 | 49,928 | 47,323 | 46,649 | 45,399 | 43,522 |
Gross Profit
| 154,934 | 137,421 | 116,489 | 106,727 | 114,240 | 109,624 | 101,049 | 91,345 | 99,227 | 90,599 | 86,158 | 75,874 | 70,495 | 67,939 | 66,781 | 65,202 | 64,684 |
Gross Profit Ratio
| 0.572 | 0.576 | 0.583 | 0.589 | 0.606 | 0.597 | 0.588 | 0.591 | 0.596 | 0.596 | 0.598 | 0.59 | 0.585 | 0.589 | 0.589 | 0.59 | 0.598 |
Reseach & Development Expenses
| 13,461 | 11,065 | 8,740 | 7,903 | 7,050 | 6,831 | 6,553 | 6,123 | 5,811 | 5,585 | 4,547 | 4,062 | 3,717 | 3,697 | 3,733 | 3,735 | 3,797 |
General & Administrative Expenses
| 47,087 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 907 | 926 | 853 | 850 | 909 |
Selling & Marketing Expenses
| 54,219 | 46,467 | 38,114 | 40,525 | 47,927 | 47,679 | 44,845 | 40,869 | 47,988 | 44,662 | 40,247 | 35,231 | 32,908 | 31,168 | 30,339 | 29,386 | 29,251 |
SG&A
| 101,306 | 46,467 | 38,114 | 40,525 | 47,927 | 47,679 | 44,845 | 40,869 | 47,988 | 44,662 | 40,247 | 35,231 | 33,815 | 32,094 | 31,192 | 30,236 | 30,160 |
Other Expenses
| 505 | -63 | 246 | 260 | -33 | -40 | 100 | 203 | -119 | 301 | 3 | 161 | 384 | 364 | 249 | 330 | -282 |
Operating Expenses
| 114,767 | 103,457 | 87,135 | 83,732 | 91,679 | 88,807 | 81,959 | 75,888 | 83,540 | 77,434 | 69,330 | 61,489 | 46,029 | 44,146 | 44,163 | 43,362 | 41,629 |
Operating Income
| 40,167 | 33,959 | 29,349 | 22,990 | 23,085 | 20,812 | 19,087 | 15,451 | 15,683 | 13,159 | 16,821 | 14,380 | 13,624 | 13,105 | 12,544 | 11,638 | 13,037 |
Operating Income Ratio
| 0.148 | 0.142 | 0.147 | 0.127 | 0.123 | 0.113 | 0.111 | 0.1 | 0.094 | 0.087 | 0.117 | 0.112 | 0.113 | 0.114 | 0.111 | 0.105 | 0.12 |
Total Other Income Expenses Net
| 1,351 | 751 | -240 | 1,139 | -1,151 | -4,514 | -2,270 | -704 | -1,383 | 586 | -2,228 | -754 | -10,378 | -10,363 | -10,206 | -12,596 | -10,687 |
Income Before Tax
| 41,518 | 34,290 | 27,953 | 23,006 | 21,730 | 16,300 | 16,820 | 14,752 | 14,303 | 13,751 | 14,599 | 13,630 | 14,088 | 13,430 | 12,412 | 9,244 | 12,368 |
Income Before Tax Ratio
| 0.153 | 0.144 | 0.14 | 0.127 | 0.115 | 0.089 | 0.098 | 0.095 | 0.086 | 0.09 | 0.101 | 0.106 | 0.117 | 0.117 | 0.109 | 0.084 | 0.114 |
Income Tax Expense
| 10,123 | 7,860 | 6,803 | 6,236 | 6,448 | 6,481 | 7,483 | 4,738 | 5,217 | 5,123 | 5,651 | 5,528 | 5,944 | 5,493 | 4,639 | 3,098 | 4,847 |
Net Income
| 30,936 | 26,377 | 21,127 | 16,743 | 15,410 | 9,799 | 9,289 | 10,011 | 9,098 | 8,631 | 8,947 | 8,087 | 8,184 | 7,966 | 7,768 | 6,139 | 7,525 |
Net Income Ratio
| 0.114 | 0.111 | 0.106 | 0.092 | 0.082 | 0.053 | 0.054 | 0.065 | 0.055 | 0.057 | 0.062 | 0.063 | 0.068 | 0.069 | 0.068 | 0.056 | 0.07 |
EPS
| 135.6 | 115.62 | 92.61 | 73.39 | 67.56 | 43 | 40.77 | 43.98 | 40.02 | 38.03 | 38.58 | 34.39 | 34.8 | 33.88 | 33.03 | 26.21 | 32.55 |
EPS Diluted
| 135.21 | 115.29 | 92.34 | 73.18 | 67.36 | 42.83 | 40.6 | 43.79 | 39.85 | 37.87 | 38.41 | 34.24 | 34.66 | 33.73 | 32.89 | 26.04 | 31.98 |
EBITDA
| 48,854 | 43,301 | 38,164 | 31,824 | 29,261 | 25,520 | 24,904 | 22,020 | 21,951 | 20,563 | 23,319 | 20,457 | 29,841 | 28,780 | 28,619 | 27,582 | 27,353 |
EBITDA Ratio
| 0.18 | 0.181 | 0.191 | 0.176 | 0.155 | 0.139 | 0.145 | 0.142 | 0.132 | 0.135 | 0.162 | 0.159 | 0.248 | 0.25 | 0.252 | 0.249 | 0.253 |